Allergan Plc (AGN)

188.03
NYSE : Health Technology
Prev Close 188.03
Day Low/High 0.00 / 0.00
52 Wk Low/High 142.81 / 217.00
Avg Volume 1.64M
Exchange NYSE
Shares Outstanding 339.44M
Market Cap 63.16B
EPS -13.20
P/E Ratio N/A
Div & Yield 2.88 (1.55%)
Aegon Announces Purchase Of Shares To Neutralize 2018 Interim Stock Dividend

Aegon Announces Purchase Of Shares To Neutralize 2018 Interim Stock Dividend

Aegon will repurchase 24,133,950 common shares to neutralize the dilutive effect of the 2018 interim stock dividend.

Allergan Announces Results Of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) For The Treatment Of Moderate To Severe Glabellar Lines

Allergan Announces Results Of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) For The Treatment Of Moderate To Severe Glabellar Lines

- Study met primary endpoint demonstrating that higher doses of BOTOX® Cosmetic produce greater duration of treatment effect -

Allergan Highlights Key Growth Drivers For Medical Aesthetics

Allergan Highlights Key Growth Drivers For Medical Aesthetics

-- Allergan Medical Aesthetics Business Has Potential to Double by 2025 Driven by Consumer Trends, Geographic Expansion and Innovation --

Allergan To Acquire Bonti Adding New Neurotoxin Programs To Medical Aesthetics Pipeline

Allergan To Acquire Bonti Adding New Neurotoxin Programs To Medical Aesthetics Pipeline

- Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan's Best-in-Class Medical Aesthetics Portfolio and Pipeline -

Allergan Unveils Spotlyte™, A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments

Allergan Unveils Spotlyte™, A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments

Spotlyte marks the first launch from Allergan digital ventures unit, Project Moonwalker™

Allergan To Host Medical Aesthetics Day Event On September 14, 2018

Allergan To Host Medical Aesthetics Day Event On September 14, 2018

DUBLIN, Sept. 10, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it will host a Medical Aesthetics Day event and webcast on Friday, September 14, 2018.

The Most Exciting Advance In Skincare Is Here: Introducing The SkinMedica® LUMIVIVE™ System

The Most Exciting Advance In Skincare Is Here: Introducing The SkinMedica® LUMIVIVE™ System

NOVEL, DUAL-ACTING PRODUCT REVITALIZES AND PROTECTS SKIN AGAINST BLUE LIGHT AND ENVIRONMENTAL AGRESSORS AROUND THE CLOCK

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.

Allergan To Present At The 2018 Morgan Stanley Global Healthcare Conference

Allergan To Present At The 2018 Morgan Stanley Global Healthcare Conference

DUBLIN, Sept. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Morgan Stanley Global Healthcare Conference in...

Allergan To Present At The 2018 Wells Fargo Healthcare Conference

Allergan To Present At The 2018 Wells Fargo Healthcare Conference

DUBLIN, Aug. 30, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Wells Fargo Healthcare Conference in Boston,...

Allergan Continues Board Refreshment Process

Allergan Continues Board Refreshment Process

-- Director Paul Bisaro to Retire from Allergan Board --

US Subsidiaries Aegon Reach Settlement With SEC

US Subsidiaries Aegon Reach Settlement With SEC

Today, US subsidiaries of Aegon reached a settlement with the Securities and Exchange Commission (SEC) in the matter of the operation and implementation of asset management quantitative models by Aegon's US asset management operations, and related...

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.

Alibaba's Domestic Focus; Allergan Takes Another Lump -- ICYMI

Alibaba's Domestic Focus; Allergan Takes Another Lump -- ICYMI

Here's what you need to know now for Thursday, Aug. 23.

Allergan Receives Complete Response Letter From The U.S. Food And Drug Administration For Ulipristal Acetate New Drug Application

Allergan Receives Complete Response Letter From The U.S. Food And Drug Administration For Ulipristal Acetate New Drug Application

DUBLIN, Aug. 21, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it received a Complete Response Letter (CRL) from the U.

Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side

Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side

Let's check out the charts again so see how far this advance might carry.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, DSS, ENDP, ICUI, PIH, SPB, SPPI, WAAS, YRD Downgrades: BMA, BRT, ELSE, FRBK, HAE, HSKA, JD, MATW, TCMD, TSG Initiations: ALT, TRTX Read on to get TheStreet Quant Ratings' detailed report:

Jim Cramer: This Is a Rotation, Not a Recession

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.

Aegon Reports Strong First Half 2018 Results

Aegon Reports Strong First Half 2018 Results

Net income amounts to EUR 491 million supported by increase in underlying earnings Underlying earnings increase by 2% to EUR 1,064 million, or 10% on constant currencies driven by expense savings, a higher investment margin in the Netherlands, performance...

Aegon To Divest Its Businesses In Czech Republic And Slovakia

Aegon To Divest Its Businesses In Czech Republic And Slovakia

Aegon has agreed to sell its businesses in Czech Republic and Slovakia for EUR 155 million to NN Group.

Here's What Was Behind Monday's Selloff

The Dow Jones Industrial Average declined by 125 points on Monday.

Aegon To Divest Last Block Of US Life Reinsurance Business

Aegon To Divest Last Block Of US Life Reinsurance Business

Aegon has agreed to divest the last substantial block of its life reinsurance business to SCOR Global Life.

Let Me Report Two of the Oddest Statistics of the Day

The first is the ISE Equity Ratio which chimed in at 213%, its first reading over 200% since January 26.

Following Up on Cimarex

So where do we go from here? We have a rule to never sell into a maelstrom.

Aegon To Divest Last Block Of US Life Reinsurance Business

Aegon To Divest Last Block Of US Life Reinsurance Business

Aegon has agreed to divest the last substantial block of its life reinsurance business to SCOR Global Life.

Allergan And Editas Medicine Announce Exercise Of Options To Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Allergan And Editas Medicine Announce Exercise Of Options To Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Reinforces both Allergan's and Editas' continued commitment to developing innovative treatments for unmet needs in eye care

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

Procter & Gamble, Western Digital, Allergan: 'Mad Money' Lightning Round

Procter & Gamble, Western Digital, Allergan: 'Mad Money' Lightning Round

Jim Cramer weighs in on Procter & Gamble, Six Flags, Western Digital, Allergan, Principal Financial Group.

Risk and Uncertainty: Cramer's 'Mad Money' Recap (Monday 7/30/18)

Risk and Uncertainty: Cramer's 'Mad Money' Recap (Monday 7/30/18)

Jim Cramer says somebody panicked, and their departure left behind a mess in the tech sector. But that spells a buying opportunity.

TheStreet Quant Rating: C (Hold)